SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines

Cancer Research

Volumn 74, Issue 22, 2014, Pages 6441-6451

  Srivastava, Abhishek K ^a,b   Dinc, Gunes ^a   Sharma, Rajesh K ^a,c   Yolcu, Esma S ^a   Zhao, Hong ^a   Shirwan, Haval ^a  

^a University of Louisville School of Medicine   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; IMMUNOLOGICAL ADJUVANT; PHOSPHORYL LIPID A; PROTEIN E7; SURVIVIN; T CELL COSTIMULATORY MOLECULE SA 4 1BBL; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; CD137 LIGAND; GAMMA INTERFERON; LIPID A; STREPTAVIDIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; IMMUNOLOGICAL MEMORY; INNATE IMMUNITY; LEWIS CARCINOMA; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; TUMOR REJECTION; ANALOGS AND DERIVATIVES; ANIMAL; AUTOIMMUNITY; IMMUNOLOGY; LUNG TUMOR; PHYSIOLOGY; SECONDARY;

4-1BB LIGAND; ADJUVANTS, IMMUNOLOGIC; ANIMALS; AUTOIMMUNITY; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; INTERFERON-GAMMA; LIPID A; LUNG NEOPLASMS; MICE; STREPTAVIDIN; T-LYMPHOCYTES, REGULATORY;

EID: 84918592462     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-1768-A     Document Type: Article

References (50)

1. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2009;27:83-117.
2. Schabowsky RH, Madireddi S, Sharma R, Yolcu ES, Shirwan H. TargetingCD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy. Curr Opin Investig Drugs 2007;8:1002-8.
3. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010;11:373-84.
4. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009;9:271-85.
5. Romanowski B, De Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009;374:1975-85.
6. Myers L, Lee SW, Rossi RJ, Lefrancois L, Kwon BS, Mittler RS, et al. Combined CD137 (4-1BB) and adjuvant therapy generates a developing pool of peptide-specific CD8 memory T cells. Int Immunol 2006;18:325-33.
7. Lee HW, Nam KO, Park SJ, Kwon BS. 4-1BB enhances CD8+ T cell expansion by regulating cell cycle progression through changes in expression of cyclins D and E and cyclin-dependent kinase inhibitor p27kip1. Eur J Immunol 2003;33:2133-41.
8. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, De Jongh BM, Drijfhout JW, et al. Vaccination with cytotoxic T lymphocyte epitopecontaining peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993;23:2242-9.
9. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996;56:21-6.
10. Sharma RK, Schabowsky R-H, Srivastava A, Elpek KG, Madireddi S, Zhao H, et al. 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines. Cancer Res 2010;70:3945-54.
11. Sharma RK, Yolcu ES, Elpek KG, Shirwan H. Tumor cells engineered to codisplay on their surface 4-1BBL and LIGHT costimulatory proteins as a novel vaccine approach for cancer immunotherapy. Cancer Gene Ther 2010;17:730-41.
12. Schabowsky RH, Elpek KG, Sharma RK, Yolcu ES, Bandura-Morgan L, Mittler RS, et al. A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab associated severe toxicity. Vaccine 2009;28:512-22.
13. Sharma RK, Elpek KG, Yolcu ES, Schabowsky R-H, Zhao H, Bandura-Morgan L, et al. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel from of 4-1BBL eradicates established tumors. Cancer Res 2009;69:4319-26.
14. Srivastava AK, Sharma RK, Yolcu ES, Ulker V, MacLeod K, Dinc G, et al. Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner. PLoS ONE 2012;7:e48463.
15. Madireddi S, Schabowsky RH, Srivastava AK, Sharma RK, Yolcu ES, Shirwan H. SA-4-1BBL costimulation inhibits conversion of conventionalCD4+T cells into CD4+FoxP3+T regulatory cells by production of IFN-gamma. PLoS ONE 2012;7:e42459.
16. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009;183:6186-97.
17. Bukczynski J, Wen T, Ellefsen K, Gauldie J, Watts TH. Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses. Proc Natl Acad SciUS A 2004;101:1291-6.
18. Cannons JL, Lau P, Ghumman B, De Benedette MA, Yagita H, Okumura K, et al. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J Immunol 2001;167:1313-24.
19. Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005;23:23-68.
20. Cohen PL, Caricchio R, Abraham V, Camenisch TD, Jennette JC, Roubey RA, et al. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J Exp Med 2002;196:135-40.
21. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007;316:1628-32.
22. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
23. Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 2009;69:2000-9.
24. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115:3623-33.
25. Powell DJ Jr, Felipe-Silva A, Merino MJ, Ahmadzadeh M, Allen T, Levy C, et al. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol 2007;179:4919-28.
26. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006;116:1935-45.
27. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003;100:8372-7.
28. Burgdorf S, Scholz C, Kautz A, Tampe R, Kurts C. Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat Immunol 2008;9:558-66.
29. Choi BK, Kim YH, Kwon PM, Lee SC, Kang SW, Kim MS, et al. 4-1BB functions as a survival factor in dendritic cells. J Immunol 2009;182:4107-15.
30. Ju S, Ju S, Ge Y, Qiu H, Lu B, Qiu Y, et al. A novel approach to induce human DCs from monocytes by triggering 4-1BBL reverse signaling. Int Immunol 2009;21:1135-44.
31. Kang YJ, Kim SO, Shimada S, Otsuka M, Seit-Nebi A, Kwon BS, et al. Cell surface 4-1BBL mediates sequential signaling pathways 'downstream' of TLR and is required for sustained TNF production in macrophages. Nat Immunol 2007;8:601-9.
32. Ma J, Bang BR, Lu J, Eun SY, Otsuka M, Croft M, et al. The TNF family member 4-1BBL sustains inflammation by interacting with TLR signaling components during late-phase activation. Sci Signal 2013;6: ra87.
33. Wilcox RA, Chapoval AI, Gorski KS, Otsuji M, Shin T, Flies DB, et al. Cutting edge: Expression of functional CD137 receptor by dendritic cells. J Immunol 2002;168:4262-7.
34. Zhang L, Wang Q, Wang X, Ding P, Song J, Ma C, et al. Anti-CD137 monoclonal antibody promotes the direct anti-tumor effect mediated by peripheral blood-derived human dendritic cells in vitro. Cell Mol Immunol 2004;1:71-6.
35. Langstein J, Becke FM, Sollner L, Krause G, Brockhoff G, Kreutz M, et al. Comparative analysis of CD137 and LPS effects on monocyte activation, survival, and proliferation. Biochem Biophys Res Commun 2000;273:117-22.
36. Imai N, Ikeda H, Tawara I, Wang L, Wang L, Nishikawa H, et al. Glucocorticoid-induced tumor necrosis factor receptor stimulation enhances the multifunctionality of adoptively transferred tumor antigenspecific CD8+ T cells with tumor regression. Cancer Sci 2009;100:1317-25.
37. Toka FN, Suvas S, Rouse BT. CD4+ CD25+ T cells regulate vaccinegenerated primary and memory CD8+T-cell responses against herpes simplex virus type 1. J Virol 2004;78:13082-9.
38. Chen X, Zhou B, Li M, Deng Q, Wu X, Le X, et al. CD4 (+) CD25 (+) FoxP3 (+) regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease. Clin Immunol 2007;123:50-9.
39. Yu P, Lee Y, Liu W, Krausz T, Chong A, Schreiber H, et al. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 2005;201:779-91.
40. Elpek KG, Lacelle C, Singh NP, Yolcu ES, Shirwan H. CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early, but not late phases of tumor development in a B cell lymphoma model. J Immunol 2007;178:6840-8.
41. Klages K, Mayer CT, Lahl K, Loddenkemper C, Teng MW, Ngiow SF, et al. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res 2010;70:7788-99.
42. Teng MW, Ngiow SF, Von SB, McLaughlin N, Sparwasser T, Smyth MJ. Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. Cancer Res 2010;70:7800-9.
43. Zhou Q, Bucher C, Munger ME, Highfill SL, Tolar J, Munn DH, et al. Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood 2009;114:3793-802.
44. Caramalho I, Lopes-Carvalho T, Ostler D, Zelenay S, Haury M, Demengeot J. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med 2003;197:403-11.
45. Gonzalez-Navajas JM, Fine S, Law J, Datta SK, Nguyen KP, Yu M, et al. TLR4 signaling in effector CD4+ T cells regulates TCR activation and experimental colitis in mice. J Clin Invest 2010;120:570-81.
46. Gough MJ, Ruby CE, Redmond WL, Dhungel B, Brown A, Weinberg AD. OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res 2008;68:5206-15.
47. Melero I, Murillo O, Dubrot J, Hervas-Stubbs S, Perez-Gracia JL. Multilayered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci 2008;29:383-90.
48. Sharma RK, Yolcu ES, Srivastava AK, Shirwan H. CD4 (+) T cells play a critical role in the generation of primary and memory antitumor immune responses elicited by SA-4-1BBL and TAA-based vaccines in mouse tumor models. PLoS ONE 2013;8:e73145.
49. Liu N, Zheng Y, Zhu Y, Xiong S, Chu Y. Selective impairment of CD4+CD25+Foxp3 +regulatory T cells by paclitaxel is explained by Bcl-2/Bax mediated apoptosis. Int Immunopharmacol 2011;11:212-9.
50. Tuve S, Chen BM, Liu Y, Cheng TL, Toure P, Sow PS, et al. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res 2007;67:5929-39.